Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein

Nature Medicine

Volumn 3, Issue 4, 1997, Pages 414-420

  Benimetskaya, Lyuba ^a   Loike, John D ^a   Khaled, Zahangir ^a   Loike, Gila ^a   Silverstein, Samuel C ^a   Cao, Long ^a   El Khoury, Joseph ^a   Cai, Tian Quan ^b   Stein, C A ^a  

^a The New York Presbyterian Hospital   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD11B ANTIGEN; CD18 ANTIGEN; CELL SURFACE RECEPTOR; INTEGRIN; OLIGONUCLEOTIDE;

ARTICLE; CELL SURFACE; HUMAN; HUMAN CELL; NEUTROPHIL; PRIORITY JOURNAL;

EID: 0030975358     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0497-414     Document Type: Article

References (10)

1. Dean, N. & McKay, R. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 11762-11766 (1994).
2. Ratajczak, M. et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 89, 11823-11827 (1992).
3. Cotter, F. et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9, 3049-3055 (1994).
4. Shoji, Y. et al. Mechanism of cellular uptake of modified oligonucleotides containing methylphosphonate linkage. Nucleic Acids Res. 19, 5543-5550 (1991).
5. Yakubov, L.A. et al. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86, 6454-6458 (1989).
6. Tonkinson, J.L. & Stein, C.A. Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22, 4268-4275 (1994).
7. Loke, S.L et al. Characterization of oligodeoxynucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86, 3474-3478 (1989).
8. Beltinger, C. et al. Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823 (1995).
9. Rappaport, J. et al. Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int. 47, 1462-1469 (1995).
10. Guvakova, M.A. et.al. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627 (1995).